Feb 22, 2024, 18:56
Raffaele Colombo: Application based on results from the TROPION-Lung01 phase 3 trial
Raffaele Colombo, Principal Scientist & Group Lead, Medicinal Chemistry at Zymeworks, shared on X/Twitter:
“Application based on results from the TROPION-Lung01 phase 3 trial.
If approved, datopotamab deruxtecan (dato-DXd) may be the first TROP2 directed antibody drug conjugate for patients with lung cancer.”
Further details.
Source: Raffaele Colombo/X
Jul 26, 2024, 00:27